KemPharm (KMPH) vs. Its Rivals Head-To-Head Survey
KemPharm (NASDAQ: KMPH) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare KemPharm to similar businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Institutional and Insider Ownership
40.0% of KemPharm shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 22.8% of KemPharm shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares KemPharm and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|KemPharm Competitors||$260.16 million||$66.28 million||-6.36|
KemPharm’s competitors have higher revenue and earnings than KemPharm. KemPharm is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
KemPharm has a beta of -1.17, indicating that its share price is 217% less volatile than the S&P 500. Comparatively, KemPharm’s competitors have a beta of 6.62, indicating that their average share price is 562% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for KemPharm and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KemPharm presently has a consensus price target of $9.00, indicating a potential upside of 140.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.94%. Given KemPharm’s stronger consensus rating and higher possible upside, research analysts plainly believe KemPharm is more favorable than its competitors.
This table compares KemPharm and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
KemPharm Company Profile
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.